publicationsSuperNovaAbstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignanciesAmerican Association for Cancer ResearchAugust 15, 2020 Learn Morelaunch
publicationsSuperNovaAbstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effectsAmerican Association for Cancer ResearchAugust 15, 2020 Learn Morelaunch
publicationsNeuroNovaASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.Abstract 21: A cell-based platform to potentiate oncolytic virus therapiesFebruary 6, 2020 AbstractlaunchPosterlaunch
publicationsSuperNovaA cell-based platform to potentiate oncolytic virus: Potential approach for cancer therapies.Journal of Clinical OncologyFebruary 4, 2020 Learn Morelaunch
publicationsNeuroNova33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.November 7, 2018 Abstractlaunch
